Equity
Total Equity
Gilead Sciences Total Equity increased by 3.6% to $23.52B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 22.7%, from $19.16B to $23.52B. Over 5 years (FY 2020 to FY 2025), Total Equity shows an upward trend with a 4.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalHigher is better
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026May 7, 2026
How to read this metric
Growth in equity generally signals value creation through profitable operations and prudent capital management.
Detailed definition
This is the residual interest in the assets of the company after deducting all liabilities, representing the net book va...
Peer comparison
Used by investors to calculate Return on Equity (ROE) and assess the company's overall financial health relative to its debt load.
Metric ID:
total_stockholders_equityHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $19.70B | $21.47B | $21.07B | $19.93B | $20.24B | $21.08B | $21.24B | $21.00B | $21.16B | $22.31B | $22.83B | $17.54B | $18.28B | $18.48B | $19.33B | $19.16B | $19.67B | $21.54B | $22.70B | $23.52B |
| QoQ Change | — | +9.0% | -1.9% | -5.4% | +1.6% | +4.2% | +0.8% | -1.1% | +0.8% | +5.5% | +2.3% | -23.2% | +4.2% | +1.1% | +4.6% | -0.9% | +2.7% | +9.5% | +5.4% | +3.6% |
| YoY Change | — | — | — | — | +2.7% | -1.8% | +0.8% | +5.4% | +4.6% | +5.8% | +7.5% | -16.5% | -13.6% | -17.2% | -15.3% | +9.3% | +7.6% | +16.6% | +17.4% | +22.7% |
Range$17.54B – $23.52B
CAGR+3.8%
Avg YoY Growth+2.2%
Median YoY Growth+5.0%
Current Streak4 quarters growth
Total Equity at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's total equity?
- Gilead Sciences (GILD) reported total equity of $23.52B in Q1 2026.
- How has Gilead Sciences's total equity changed year-over-year?
- Gilead Sciences's total equity increased by 22.7% year-over-year, from $19.16B to $23.52B.
- What is the long-term trend for Gilead Sciences's total equity?
- Over 5 years (2020 to 2025), Gilead Sciences's total equity has grown at a 4.5% compound annual growth rate (CAGR), from $18.20B to $22.70B.
- What does total equity mean?
- The total net value of the company belonging to its shareholders after all debts are paid.